President Trump’s Executive Order: Frequently Asked Questions

What it means and doesn’t mean for the Veteran Community

In the days since President Donald Trump announced an Executive Order in support of breakthrough therapies, we’ve heard from many of you with thoughtful questions about what it means and what, if anything, has changed. We’re encouraged to see so much engagement and care around this topic. That said, there’s a lot of noise and mixed information circulating. We put this FAQ together to offer clear answers about what this moment represents, what it does and does not change, and how it relates to the pathways that exist today.

1) Why is everyone talking about this executive order?

This is a meaningful moment for veterans and mental health care in the U.S.

For the first time at this level, the federal government is signaling that new approaches, including psychedelic therapies, are worth serious consideration for treating conditions like PTSD, depression, and substance use disorders, especially for those who have not found relief through existing options.

It reflects years of effort, research, and advocacy from veterans, clinicians, and organizations working to expand access to better care and to move psychedelic research into the mainstream in a responsible, evidence-based way.

2) Does this mean psychedelic therapy is now legal?

No. The executive order does not legalize psychedelics.

It focuses on accelerating research and regulatory review for substances like psilocybin, MDMA, and ibogaine. These treatments still need to go through the FDA approval process, and even if approved, access will likely roll out gradually as systems build the capacity to deliver them safely.

That includes trained providers, appropriate care models, clinic infrastructure, and coverage decisions from insurers and the VA.

3) What actually changed?

The biggest shift is the positive recognition at the federal level and the momentum this executive order brings.

The order prioritizes faster FDA review for promising psychedelic treatments, expands funding for research, encourages coordination between agencies like the VA and FDA, and opens pathways for limited, pre-approval access for eligible patients. For a field that has moved slowly for decades, this is a significant step forward, though most people will not see immediate changes in how they can access treatment.

4) Will the VA start offering psychedelic therapy soon?

Not yet.

The VA is being encouraged to continue research and prepare for future integration of these treatments, but no psychedelic therapies are currently approved within the VA or other healthcare settings.

Some veterans may be able to participate in research studies already happening within or in partnership with VA systems as well as studies happening in academic institutions.   

Bringing these treatments into standard VA care will still take time and require FDA approval, provider training, established care models, and the infrastructure to deliver them safely.

5) Which substances are being studied?

Current research in this space includes psilocybin, MDMA, and now ibogaine. 

The executive order more broadly supports research into psychedelic therapies as potential treatmentsbeing studied for PTSD, depression, substance use disorders, and traumatic brain injury. This mainly focuses on pharmaceutical-grade or synthetic versions of these compounds being developed and studied within clinical and regulatory pathways, which differ from plant-based or naturally derived forms currently used in certain legal settings.

6) Why is ibogaine getting so much attention?

Ibogaine is receiving increased attention for a few reasons.

High profile veterans have been especially vocal about their experiences with it, and early research in veteran populations has shown promising results across PTSD, depression, anxiety, and traumatic brain injury. It also has a longer history of being used in the context of substance use and opiate withdrawal.

It has also, at times, been viewed differently from other psychedelics because it is not associated with recreational use in the same way, and the experience itself is often described as physically and psychologically intense. That distinction has influenced how it is perceived and discussed in policy and medical conversations.

It should also be stated that ibogaine is one of the more medically complex treatments being discussed. It can have significant effects on the heart and requires thorough medical screening, monitoring, and experienced providers to be administered safely. It is not the right fit for everyone.

There are other psychedelic treatments that are further along in research and have more established safety profiles that will reach patients sooner. This is important context as attention grows.

At HHP, the focus is not on any single medicine. Veterans deserve access to a range of safe, evidence-based options, and the goal is to help build pathways to all of them.

7) Can veterans access psychedelic treatment right now?

Yes, but through specific and limited pathways.

Current options in the US include clinical and research trials and state regulated programs such as psilocybin services in Oregon. There are also international retreats where certain psychedelics  are legal. Veterans and their family members are also turning to programs like Heroic Hearts Project, which provide structured retreat experiences along with preparation and integration support specifically designed for the veteran community.

The executive order does not immediately expand access, but it may increase options over time.

8) Does this change how quickly access might expand?

Not immediately, though there are early signs of movement. As of April 24, the FDA has begun taking steps to expedite aspects of its review process for psychedelic therapies that have received Breakthrough Therapy designation, following the executive order.

The goal of the order is to reduce delays in research and approval while expanding access to certain investigational treatments for qualified patients. Over time, this could lead to more opportunities to access care with fewer barriers.

At the same time, it is important to understand the timelines involved. Clinical research studies can take several years to complete and publish, and the FDA approval process has historically taken a decade or more. While this order aims to accelerate that process, it will still take time before these efforts translate into wider, more consistent access.

For now, most access continues to happen through the pathways available today.

9) Will the government or insurance cover these treatments?

Not yet.

The order includes funding for research, but coverage through the VA or insurance will depend on FDA approval, clinical guidelines, and future policy decisions.

Ensuring that care is not just available but also affordable is a key part of what still needs to be built.

10) Does this mean veterans will not need to travel overseas anymore?

Many veterans currently travel abroad for treatments like psilocybin  because they are not available in the U.S. This order is a step toward creating safe and regulated access domestically, but that system will take time to develop.

However, we believe  access should not be one size fits all. Some veterans feel strongly drawn to international programs, including those connected to indigenous traditions and contexts, while others will benefit most from options that are available closer to home or within established healthcare systems with their health care providers.

The goal is to ensure veterans have real choice, along with meaningful access and affordability across safe, legal, and well-supported options, so more people can receive the care that is right for them.

11) What needs to happen before these treatments are widely available?

In the near term, we may see more clinical trials and research.

Widespread availability, especially through systems like the VA, will require FDA approvals, trained providers, and scalable care models. This is where the real work begins. Translating promising research into safe, accessible care is where progress either accelerates or stalls, and where investments in training, infrastructure, and delivery models become just as important as the science itself.

12) What does this mean for the HHP community right now?

It is a sign that the direction this community has been moving in is gaining broader recognition.

For years, veterans in the HHP community have been engaging with structured, legal psychedelic programs, both internationally and in state regulated settings, supported by preparation and integration. That work has helped demonstrate what safe, intentional care can look like in practice.

At the same time, efforts are underway across the field to bring these treatments into more traditional systems like the VA. Those pathways will take time to build, but they are moving in parallel.

To help move that work forward and ensure veterans remain at the center of shaping this care, veterans, family members, and supporters can get involved with Healing Breakthrough, our federal advocacy arm, and support our efforts to bring these treatments into the VA

13) What if any impact will this have on current or upcoming HHP retreats?

This executive order does not have a direct impact on current or upcoming retreat programs.

For those already enrolled in HHP programs, your experience remains the same. 

Alongside these programs, HHP continues to contribute to research with institutions like the University of Texas Dell Medical School and the University of Colorado Boulder.

These studies are an important part of building the evidence base needed to expand safe, legal access to psychedelic care over time. This is why optional participation in research is so valuable. We encourage participants to consider taking part if it feels right for them, as it is one of the ways this community contributes directly to future progress.

Participation is always optional, and your experience in the program is not dependent on whether you choose to participate in research.

In Summary

This is a meaningful step forward, but it is not the finish line.

Real progress will depend on what comes next, including continued research, thoughtful implementation, and building systems that make these treatments safe, accessible, and affordable for the veterans who need them. That work is already underway, and this community is part of it.

We will continue to share updates as this evolves. In the meantime, we remain focused on what matters most: supporting veterans and their families through safe, structured programs and expanding access to care that works.